Monthly Archives: December 2017


Michel M.P.J. Reijnen, MD, PhD Vascular Surgeon, Rijnstate Hospital, Arnhem, The Netherlands. Issue Volume 14 – Issue 8 – August 2017 Citation Vascular Disease Management. 2017;14(8):e189-e191. The SUPERB Study The SUPERB trial is a multicenter randomized trial that was designed to prove the concept of endoluminal bypass with the heparin-bonded Gore Viabahn self-expanding endoprosthesis in… Read More »

Vascular Successful results for Aortica’s AortaFit FEVAR planning software

     Benjamin Starnes, chief of Vascular Surgery at the University of Washington (Seattle, USA), has reported successful results for the first 30 patients undergoing fenestrated endovascular aneurysm repair (FEVAR) planned and performed using Aortica’s AortaFit automated case planning software. The cases are part of Starnes’ US Food and Drug Administration (FDA)-approved physician-sponsored investigational device exemption… Read More »

Radiation During EVAR Damages Operators’ DNA

A study published in Circulation has shown for the first time that an acute DNA damage response occurs in operators performing fluoroscopically-guided interventions such as endovascular aortic repair (EVAR). Leg shielding may have a protective effect though, the researchers said. DNA damage/repair markers were measured in circulating lymphocytes of operators at several times—before performing endovascular and open… Read More »

Evolocumab becomes first PCSK9 inhibitor to be approved for use in the USA to prevent myocardial infarction

The US FDA has approved evolocumab (Repatha, Amgen) for the prevention of myocardial infarction, strokes and coronary revascularisations in adults with established cardiovascular disease. The approval means that the drug is now the first PCSK9 inhibitor to have such an indication in the USA. A press release reports that the FOURIER study showed that evolocumab… Read More »